AMMAN —
Hikma Pharmaceuticals, a
multinational pharmaceutical company, reported its interim results on Thursday,
which showed a strong performance in H1 of 2023.
اضافة اعلان
According to a press statement, the group
said that revenue went up by 18 percent with strong growth in all three
business segments, reaching $1.427 billion, compared to the $1.213 billion
recorded in H1 of 2022, Jordan News Agency, Petra reported.
Said Darwazah, Executive Chairman and Chief
Executive Officer of
Hikma, said: "Our strong first half performance
reflects growth across all three of
Hikma’s businesses and geographies. Across
our global operations we have continued to strengthen our businesses and
processes, including adding to, and enhancing our manufacturing
capabilities."
"Our investments in research and
development have yielded several new product launches and pipeline expansion,
broadening our differentiated product portfolio. We continue to win important
new contracts and expand in new markets, all of which are
enabling Hikma to
make more medicines accessible to the healthcare providers and patients who
need them most," he pointed out.
Read more National news
Jordan News
.jpg)
.jpg)
